Relmada Therapeutics (id:8379 RLMD)
2.80 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 7:21:30 PM)
Exchange closed, opens in 14 hours 8 minutes
1.82 USD (1.82%)
-7.28 USD (-7.28%)
-20.00 USD (-20.00%)
-8.20 USD (-8.20%)
-5.08 USD (-5.08%)
-90.30 USD (-90.30%)
-95.33 USD (-95.33%)
-95.33 USD (-95.33%)
About Relmada Therapeutics
Market Capitalization 95.35M
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
| Headquarters (address) |
2222 Ponce de Leon Boulevard Coral Gables 33134 FL United States |
| Phone | 786-629-1376 |
| Website | https://www.relmada.com |
| Employees | 20 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | RLMD |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.88 - 7.22 |
| Market Capitalization | 95.35M |
| P/E trailing | -0.854 |
| P/E forward | -1.57 |
| Price/Book | 1.11 |
| Beta | 0.415 |
| EPS | -2.86 |
| EPS United States (ID:6, base:3402) | 24.22 |